» Articles » PMID: 27079322

Characterization of Mesenchymal Stromal Cells: Potency Assay Development

Overview
Journal Transfusion
Specialty Hematology
Date 2016 Apr 16
PMID 27079322
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Based on their many different mechanisms of action, presumed immune-privileged status, and relative ease of production, mesenchymal stromal cells (MSCs) are under intensive clinical investigation for treating a wide range of degenerative, inflammatory, and immunologic disorders. Identification of relevant and robust potency assays is not only a regulatory requirement, but it is also the basis for producing and delivering a product that is consistent, safe, and ultimately an effective therapy. Although development of an appropriate potency assay is one of the most challenging issues in cell-based therapies, it is of paramount importance in the process of developing and testing cellular products. Regardless of the many different tissue sources and methods used in culture expansion of MSCs, they possess many of the same morphologic, cell surface markers, and differentiation characteristics. However, MSC products with similar phenotypic characteristics could still have major differences in their biologic and functional attributes. Understanding the different mechanisms of action and establishment of relevant potency assays is of pivotal importance in allowing investigators and regulatory agencies to compare MSCs used in different clinical trials.

Citing Articles

The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review.

cesnik A, Svajger U Front Cell Dev Biol. 2024; 12:1400347.

PMID: 39129786 PMC: 11310176. DOI: 10.3389/fcell.2024.1400347.


Illustrative Potency Assay Examples from Approved Therapies.

Torrents S, Grau-Vorster M, Vives J Adv Exp Med Biol. 2023; 1420:139-149.

PMID: 37258788 DOI: 10.1007/978-3-031-30040-0_9.


Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use.

Torrents S, Del Moral A, Codinach M, Rodriguez L, Querol S, Vives J Immunol Res. 2023; 71(5):725-734.

PMID: 37120479 PMC: 10148700. DOI: 10.1007/s12026-023-09385-1.


Characterization of Intestinal Mesenchymal Stromal Cells From Patients With Inflammatory Bowel Disease for Autologous Cell Therapy.

Anbazhagan M, Geem D, Venkateswaran S, Pelia R, Kolachala V, Dodd A Stem Cells Transl Med. 2023; 12(2):112-122.

PMID: 36869704 PMC: 9985114. DOI: 10.1093/stcltm/szad003.


Skin-Derived ABCB5 Mesenchymal Stem Cells for High-Medical-Need Inflammatory Diseases: From Discovery to Entering Clinical Routine.

Niebergall-Roth E, Frank N, Ganss C, Frank M, Kluth M Int J Mol Sci. 2023; 24(1).

PMID: 36613507 PMC: 9820160. DOI: 10.3390/ijms24010066.